Objective:

To evaluate the efficacy of ixekizumab plus tirzepatide in achieving simultaneous complete skin clearance and weight reduction in adult patients with moderate to severe plaque psoriasis and obesity, focusing on the potential benefits of combination therapy.

Key Findings:

• 27% of participants receiving ixekizumab plus tirzepatide achieved the primary endpoint vs 6% receiving ixekizumab alone, with a 21% absolute difference.

Interpretation:

Concomitant administration of ixekizumab plus tirzepatide was superior to ixekizumab alone in achieving key efficacy outcomes at 36 weeks, with no new safety concerns identified, highlighting its potential as a treatment option.

Limitations:

• Open-label design may introduce bias; more imputed data in the ixekizumab-only group could affect results; absence of a tirzepatide monotherapy group limits assessment of its direct effects on psoriasis severity; exclusion of patients with inadequate response to IL-17 inhibitors may limit generalizability.

Conclusion:

Combination therapy with ixekizumab and tirzepatide shows promise in treating psoriasis and obesity, warranting further investigation to confirm these findings.